Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H. Maruyama D, et al. Among authors: takamatsu y. Br J Haematol. 2021 Feb;192(3):531-541. doi: 10.1111/bjh.16878. Epub 2020 Jun 24. Br J Haematol. 2021. PMID: 32583431 Free PMC article. Clinical Trial.
THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Eur J Haematol. 2010 May;84(5):391-7. doi: 10.1111/j.1600-0609.2010.01411.x. Epub 2010 Jan 5. Eur J Haematol. 2010. PMID: 20059527 Clinical Trial.
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Int J Hematol. 2010 Oct;92(3):503-9. doi: 10.1007/s12185-010-0673-y. Epub 2010 Sep 8. Int J Hematol. 2010. PMID: 20824401 Clinical Trial.
Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG). Muta T, et al. Among authors: takamatsu y. Intern Med. 2013;52(1):63-70. doi: 10.2169/internalmedicine.52.8390. Epub 2013 Jan 1. Intern Med. 2013. PMID: 23291675 Free article.
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. Nagafuji K, et al. Among authors: takamatsu y. J Hematol Oncol. 2013 Feb 6;6:14. doi: 10.1186/1756-8722-6-14. J Hematol Oncol. 2013. PMID: 23388549 Free PMC article.
507 results